In a recent transaction, Boughton Soleil, the Chief Legal Officer of Hims & Hers Health, Inc. (NYSE:HIMS), sold shares of the company's stock valued close to $100,000. The sale, which took place on May 20, 2024, involved a total of 4,915 shares of Class A Common Stock at an average weighted price of approximately $20.0148, resulting in a total transaction value of $98,372.
The shares were sold at prices ranging between $20.00 and $20.045, as per the details provided in the footnotes of the filing. The executive has also undertaken to provide full information regarding the number of shares sold at each separate price upon request.
Before the sale, Boughton Soleil exercised options to acquire the same number of shares at a price of $5.01 per share, amounting to a total of $24,624. This transaction was executed in accordance with a Rule 10b5-1 trading plan adopted on September 10, 2023.
Following the sale, the Chief Legal Officer's ownership in the company stands at 159,357 shares of Class A Common Stock. Additionally, the executive holds derivative securities in the form of stock options, which are subject to a service-based vesting requirement over a four-year period. Post-transaction, the total number of shares owned following derivative transactions is 964,076.
Investors and followers of Hims & Hers Health, Inc. often monitor such insider transactions as they provide insights into the executives' perspectives on the company's current valuation and future prospects.
InvestingPro Insights
Amidst the insider trading activity at Hims & Hers Health, Inc., the market is also reflecting significant movements in the company's stock. According to real-time data from InvestingPro, Hims & Hers Health, Inc. has been experiencing robust growth with a 55.65% increase in revenue over the last twelve months as of Q1 2024. This is complemented by a substantial 82.41% gross profit margin, showcasing the company's ability to maintain profitability on its sales.
Moreover, the stock has shown a remarkable 90.38% one-year price total return, which aligns with the InvestingPro Tip that highlights a strong return over the last year. This could be a contributing factor to why insiders might consider the timing right for transactions. Additionally, analysts have revised their earnings upwards for the upcoming period, which is another InvestingPro Tip that suggests growing confidence in the company's financial performance.
For those considering an investment in Hims & Hers Health, Inc., it's worth noting that the stock is currently trading at a high Price / Book multiple of 10.94, which might warrant a closer look at the company's valuation metrics. With these insights and more available tips, investors can further analyze the stock's potential by visiting https://www.investing.com/pro/HIMS. For a deeper dive into the company's financials and to unlock additional InvestingPro Tips, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. There are currently 15 more InvestingPro Tips listed for Hims & Hers Health, Inc., providing a comprehensive analysis for informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.